SCHEMBL3929007

SCHEMBL3929007

Cc1ccc(-c2cc3ncnc(NCCc4c(C)[nH]c5c(F)ccc(C)c45)c3s2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 9/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TYK2 P29597 1/20 0.41
EGFR P00533 4/20 0.36
STK17B O94768 2/20 0.36
FLT1 P17948 2/20 0.35
NTRK1 P04629 2/20 0.35
KDR P35968 1/20 0.34
AURKA O14965 1/20 0.34
AURKB Q96GD4 1/20 0.34
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930461 0.97 NPC1 (0.42) FDPSNPC1RAB9ATYK2EGFR
SCHEMBL3936128 0.94 NPC1 (0.43) FDPSNPC1RAB9ATYK2EGFR
SCHEMBL3939022 0.93 NPC1 (0.45) FDPSNPC1RAB9ATYK2EGFR
SCHEMBL4073363 0.92 NPC1 (0.43) FDPSNPC1RAB9ATYK2EGFR
SCHEMBL4068409 0.91 TYK2 (0.53) NPC1RAB9ATYK2EGFRFLT1
SCHEMBL3937751 0.91 NPC1 (0.46) FDPSNPC1RAB9ATYK2EGFR
SCHEMBL4069307 0.90 NPC1 (0.46) NPC1RAB9ATYK2EGFRSTK17B
SCHEMBL3937781 0.89 PRKCI (0.44) NPC1RAB9ATYK2EGFRSTK17B
SCHEMBL4065656 0.89 FLT1 (0.45) NPC1RAB9ATYK2EGFRSTK17B
SCHEMBL4071195 0.89 FLT1 (0.46) NPC1RAB9ATYK2EGFRSTK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 FDPS 2673/4885NPC1 2246/4885RAB9A 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.